Le Lézard
Classified in: Health
Subject: FDA

OrthoGrid Systems' PhantomMSKtm Platform Receives FDA 510(k) Clearance for Novel Distortion Adaptation Technology in Orthopedic Surgery

SALT LAKE CITY, Feb. 26, 2019 /PRNewswire-PRWeb/ -- OrthoGrid Systems, Inc., a leading innovator in intraoperative surgical imaging, workflow efficiency and decision-making support in orthopedic surgery, today announced that the US Food & Drug Administration has granted a 510(k) clearance for the company's novel PhantomMSKtm Orthopedic Platform. As a result of this critical milestone, OrthoGrid intends to embark on a national educational campaign about the importance of recognizing and correcting for fluoroscopic (x-ray) distortion for physicians performing orthopedic surgery.

"Fluoroscopy is utilized in most Direct Anterior Approach hip arthroplasty procedures, as it reveals real-time implant position and anatomic landmarks. But until now, there has been virtually no method to correct the highly variable distortion present in all fluoroscopic x-rays due to electromagnetic interference," noted Charlotte-based orthopedic surgeon, John Masonis, MD. "The PhantomMSKtm System has achieved a new level of functionality with the novel distortion adaptation tool, and I am pleased to bring this important technological development to my patients."

In the USA, millions of orthopedic surgeries are performed each year in hospitals and ambulatory surgical centers, and the majority of these procedures utilize radiography. The now-510(k) cleared PhantomMSKtm System currently provides assistance in multiple procedures, including the fast-growing direct anterior approach total hip arthroplasty surgery, where it aims to help restore native hip biomechanics with alignment considerations for leg length, femoral offset, cup inclination, femoral abduction, pelvic tilt, and pelvic obliquity.

"- Adding the PhantomMSKtm System to our portfolio of solutions with this critical 510(k) clearance represents a new era for the company, and we expect to reach thousands of orthopedic physicians this year with deliberate education that highlights the science and benefits associated with our unique and patented distortion adaptation technology, added OrthoGrid Co-CEO, Richard Boddington. We invite any interested clinicians to visit us at the 2019 American Academy of Orthopedic Surgeons (AAOS) meeting where we will be providing daily demonstrations in booth #625.

About OrthoGrid Systems, Inc.

OrthoGrid Systems is a rapidly expanding global leader in intraoperative imaging technologies targeting component and anatomic alignment, imaging efficiency, optimized visualization and decision-making support for orthopedic surgery. OrthoGrid specializes in leveraging the latest innovation in technology to create practical and efficient solutions available or in development for hip arthroplasty, hip preservation, trauma and other standard procedures performed over 10 million times per year globally. Learn more about OrthoGrid and our products by visiting our website at http://www.orthogrid.com.


SOURCE OrthoGrid Systems, Inc.

These press releases may also interest you

at 12:00
In lieu of an in-person update to the media, Dr. Theresa Tam, Canada's Chief Public Health Officer, issued the following statement today: "There have been 105,091 cases of COVID-19 in Canada, including 8,663 deaths. 65% of people have now recovered....

at 11:00
The latest data of the evolution of COVID-19 in Québec reveal 102 new cases over the past 24 hours, bringing the total number of people infected to 55,784. During the same period, 3 new deaths were recorded, to which are added 3 deaths that occurred...

at 10:37
On Friday, the British government announced that, as of July 10th, those travelling from the Commonwealth of Dominica to England need not self-isolate for 14 days. Dominica is one of the 59 countries and 14 British Overseas Territories forming a...

at 03:05
Gilead Sciences, Inc. today announced data from an ongoing Phase 1 study, which showed that a sustained-delivery subcutaneous formulation of the company's investigational, novel inhibitor of HIV-1 capsid function, lenacapavir (GS-6207), sustained...

at 03:05
Gilead Sciences, Inc. today announced data demonstrating the safety and efficacy of the once-daily, single tablet regimen Biktarvy® (bictegravir 50 mg/emtricitabine 200 mg/tenofovir alafenamide 25 mg tablets, B/F/TAF) in virologically suppressed...

3 jui 2020
Daiya Foods Inc. is recalling Daiya brand Classic Vanilla Creme Non-Dairy Frozen Dessert from the marketplace because it contains milk which is not declared on the label. People with an allergy to milk should not consume the recalled product...

News published on 26 february 2019 at 10:00 and distributed by: